|
¹Ý¼®½áÄ¡(ÁÖ) |
[NGS¿¬±¸¿ø]ÄÚ½º´Ú¹ÙÀÌ¿À»óÀå»ç(¼¿ï)
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
»ó½Ãä¿ë |
02.21 |
|
|
JN Partners |
[¹ÙÀÌ¿À»ç] Àü·«±âȹ ÆÀÀå±Þ
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°æ¿µ/Àü·«±âȹ/ÄÁ¼³Æà |
5³â¡è |
ä¿ë½Ã |
02.16 |
|
|
JN Partners |
BT ¿¬±¸¼Ò ¿¬±¸¿ø (¹Ú»ç±Þ)
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
11.07 |
|
|
(ÁÖ)ºñºñÆÄÆ®³Ê½º |
[¿Ü±¹°è/µ§Å»] RA (1~5yr)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
1³â¡è |
ä¿ë½Ã |
10.19 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
ºÐÀÚÁø´Ü½Ã¾àÁ¦Á¶»ç ÃßÃâ½Ã¾à »ý»ê°æ·ÂÀÚ ¸ðÁý
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
¼ö½Ãä¿ë |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.14 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
Pharmacovigilance (MI) Specialist / Regulatory Affairs
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
5³â¡è |
ä¿ë½Ã |
03.14 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
RA (1³â °è¾àÁ÷)
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
3³â¡è |
ä¿ë½Ã |
11.14 |
|
|
Çì´Ï¾Ø¸ÓÄÚÀÌ |
CRA (Clinical Research Associate)
¼¿ï °³²±¸, ¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
09.18 |
|
|
(ÁÖ)À¯´ÏÄÚ½á¾îÄ¡ |
[±¹³» ¹ÙÀÌ¿À Á¦¾àȸ»ç] ±Û·Î¹ú »ç¾÷°³¹ß ÀÓ¿ø
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
17³â¡è |
ä¿ë½Ã |
03.28 |
|
|
(ÁÖ)¿¡ÄÚ½áÄ¡ |
¿Ü±¹°èÁ¦¾àȸ»ç/Local Trial Manager(ÀÓ»ó)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
8³â¡è |
ä¿ë½Ã |
11.29 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
´ç´¢ÆÀ MSL Manager/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
5³â¡è |
ä¿ë½Ã |
03.11 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Oncology Brand Manager(Æó¾Ï½ÅÁ¦Ç°)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
5³â¡è |
ä¿ë½Ã |
12.12 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
RA Specialist(Á¤±ÔÁ÷)/±Û·Î¹ú¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
3³â¡è |
ä¿ë½Ã |
12.12 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
È£Èí±âMSL/Global¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
1³â¡è |
ä¿ë½Ã |
12.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
PR Specialist/Global¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
±¤°í/È«º¸/PR/»çº¸ |
2³â¡è |
ä¿ë½Ã |
11.02 |
|